Current Clinical Trials

Studies listed below are currently open to accept new study patients. If you believe you might meet the baseline criteria, or would simply like more information, please contact us.

Condition Study Name Criteria Additonal Information
Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, Type 2 Diabetes Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, With or Without Type 2 Diabetes
  • Age above or equal to 45 years
  • Have a BMI >27.0 kg/m2
  • Participants have established atherosclerotic cardiovascular disease ASCVD and/or chronic kidney disease CKD as evidenced at least one of the following:
    • Coronary artery disease
    • Cerebrovascular disease
    • Peripheral arterial disease
    • Chronic kidney disease
  • Does not have acute decompensated heart failure requiring hospitalization.
  • Does not have ave New York Heart Association (NYHA) Classification Class IV heart failure
  • Kidney related:
    • Participant does not have an eGFR <20 mL/min/1.73 m^2
    • Does not have UACR >5000 mg/g 
    • Does not have received any form of dialysis within 90 days
    • Does not have either undergone a kidney transplant or have a transplant procedure scheduled
  • Other medical conditions:
    • Participants have not had or do not plan to have a surgical treatment for obesity.
    • Do not ahve a history of chronic or acute pancreatitis
    • Do not have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2
    • Do not have a known clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction
  • There will be about 34 study visits, 19 office and 15 phone visits over about five years.
  • Patients may be compensated for each completed visit.
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost.
  • Patients will be directed to their own doctor for normal care/non-study related health concerns.
Atrial Fibrillation Atrial Fibrillation
  • Atrial fibrillation or flutter, paroxysmal or sustained not due to a reversible cause, and eligible to receive anticoagulation therapy

  • Patient must satisfy one or both of the following categories of risk factors:
    • Age ≥75 years at the time of screening
    • History of a clinical symptomatic stroke of any type.
  • OR

  • Patient must satisfy two or more of the following categories of risk factors:
    • Age between 65 and 74 years
    • Hypertension
    • Diabetes mellitus
    • Atherosclerotic vascular disease meeting one or more of the following criteria: a) Lower extremity PAD or b) prior major vascular amputation, peripheral bypass, or peripheral percutaneous
    • And/Or CAD, MI, CABG, PCI
  • Does not have a history of any of the following only if within 3 months of randomization: primary hemorrhagic stroke, hemorrhagic transformation of an ischemic stroke, subarachnoid hemorrhage, subdural hematoma, spinal cord hemorrhage.

  • Does not have any condition other than AF that requires chronic anticoagulation
  • Does not have current active liver disease (eg, acute hepatitis, known cirrhosis), including participants receiving antiviral treatment for hepatitis.
  • There will be about 20 office visits over about 4 years
  • Patients may be compensated up to $70 per office visit
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
  • Patients will be directed to their own doctor for normal care/non-study related health concerns
Chronic Kidney Disease, Type 2 Diabetes & Obesity Chronic Kidney Disease, Type 2 Diabetes & Obesity
  • Body mass index (BMI) ≥ 27.0 kilograms per meter square (kg/m^2) at screening. BMI will be calculated in the eCRF (electronic case report form) based on height and body weight at screening.
  • HbA1c less than or equal to (≤) 10.5% (91 millimoles per mole [mmol/mol]) as assessed by central laboratory at screening.
  • Kidney impairment defined by serum creatinine and cystatin C-based eGFR ≥ 15 and < 90 milliliters per minutes per 1.73^m^2 (mL/min/1.73 m^2) (CKD-EPI 2021) as assessed by central laboratory at screening.
  • Treatment with maximum labelled or tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated, in the opinion of the investigator. Treatment dose must be stable for at least 30 days prior to screening.
  • No congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations.
  •  No use of any glucagon-like peptide-1 receptor agonist (GLP-1RA) (including medication with GLP-1RA activity, e.g., GIP/GLP-1RA) or amylin analogue within 60 days prior to screening.
  • No uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • There will be about 13 study visits, 13 office visits over about 35 weeks.
  • Patients may be compensated for each completed visit.
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
  • Patients will be directed to their own doctor for normal care/non-study related health concerns
Lipoprotein(a) [Lp(a)] and Atherosclerotic Cardiovascular Disease (ASCVD) Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
  • Age above or equal to 18
  • Have Lipoprotein(a) [Lp(a)] ≥175 nanomoles per liter (nmol/L).
  • Meet criteria of either 2a or 2b:

2a: Individuals 18 years of age or older with established atherosclerotic cardiovascular disease (ASCVD) with an event or revascularization.

2b: Individuals 55 years of age or older who are at risk for a first cardiovascular (CV) event and either: Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without history of event or revascularization; known familial hypercholesteremia; or a combination of high-risk factors.

  • Have not had a major cardiovascular event or surgery, such as myocardial infarction (MI), stroke or coronary or peripheral revascularization, < 90 days before screening.
  • Do not have uncontrolled hypertension
  • Does not have New York Heart Association class IV heart failure.
  • Does not have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease, or any of these laboratory results as determined by the central laboratory at screening.
  • There will be about 25 study visits, 18 office and 7 phone visits over about four years
  • Patients may be compensated up to $1,428.00.00 if all visits are completed.
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost.
  • Patients will be directed to their own doctor for normal care/non-study related health concerns.
Obesity and Cardiovascular Disease Obesity and Cardiovascular Disease
  • 55 years of age or older
  • Body mass index (BMI) ≥ 30
    1. Established CVD as evidenced by at least one of the following: Prior myocardial infarction, prior stroke (ischemic or hemorrhagic stroke), or Symptomatic peripheral arterial disease (PAD)
  • If diabetic:
    • Diagnosed with type 2 diabetes ≥ 180 days ago
    • HbA1c 7%-10%
  • No planned coronary, carotid or peripheral artery revascularization
  • Not being treatmed with any glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or a medication with GLP-1 activity within 90 days
  • No chronic or intermittent hemodialysis or peritoneal dialysis
  • There will be about 22 study visits over about 3 years
  • Patients may be compensated up to $1,100.00 if all visits are completed
  • Patients will receive lab tests, diabetes medications, physical exams, and study related care at no cost
  • Patients will be directed to their own doctor for normal care/non-study related health concerns
Parkinson's Disease Parkinson's Disease (PD) - Online Study
  • Male or female over the age of 18
  • Diagnosis of Parkinson’s disease
  • Has Internet access to provide data online

For more information please visit:  www.foxinsight.org/clinic

  • Surveys on health-related topics to be completed every 3 months for 5 years
  • Optional, one-time surveys and sub-studies including genetic testing and counseling at no cost
  • Appointment reminders and physician reports online for patients